Zobrazeno 1 - 10
of 156
pro vyhledávání: '"J J, Kavanagh"'
Publikováno v:
International Journal of Gynecologic Cancer. 18:460-464
The topoisomerase I agents are established as a therapy in recurrent ovarian cancer. Karenitecin, an analog of topotecan with solubility and pharmacologic advantages, was tested in a phase II trial in previously treated patients with recurrent or per
Publikováno v:
International Journal of Gynecologic Cancer. 16:458-471
Venous thromboembolism (VTE) could be presented as an initial clinical feature in some cancer patients or a complication followed by various cancer treatments, which all indicates a poor outcome. This review focuses on elucidating the relationship of
Publikováno v:
International Journal of Gynecologic Cancer. 16:295-299
Distant metastasis to sites other than lymph nodes of borderline ovarian tumor is rare. We describe a case metastasized to sigmoid colon mucosa and submucosa. The metastatic lesion was detected incidentally by screening colonoscopy 7 years after the
Autor:
J. J. Kavanagh, D. M. Gershenson, H. Choi, L. Lewis, K. Patel, G. L. Brown, A. Garcia, D. R. Spriggs
Publikováno v:
International Journal of Gynecologic Cancer. 15:593-600
The purpose of this study was to determine the safety and efficacy of TLK286 (TELCYTA™), a glutathione analog prodrug, in patients with platinum and paclitaxel refractory or resistant ovarian carcinoma. Thirty-six patients with measurable disease w
Autor:
H. T. See, R. S. Freedman, A. P. Kudelka, T. W. Burke, D. M. Gershenson, S. Tangjitgamol, J. J. Kavanagh
Publikováno v:
International Journal of Gynecologic Cancer. 15:209-216
The objective of the analysis was to determine the effectiveness of re-treating patients with ovarian cancer, primary peritoneal cancer, and fallopian tube cancer with carboplatin after being deemed platinum resistant. From a database period January
Autor:
S. Tangjitgamol, P. T. Ramirez, C. C. Sun, H. T. See, A. Jhingran, J. J. Kavanagh, M. T. Deavers
Publikováno v:
International Journal of Gynecologic Cancer. 15:646-656
We studied the immunohistochemical expression of HER-2/neu, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), cyclooxygenase-2 (COX-2), estrogen receptor (ER), and progesterone receptor (PR) in uterine cervical small
Autor:
E.-J. Lee, G. Kong, S.-H. Lee, S. B. Rho, C.-S. Park, B.-G. Kim, D.-S. Bae, J. J. Kavanagh, J.-H. Lee
Publikováno v:
International Journal of Gynecologic Cancer. 15:146-154
Uterine leiomyomas are very common benign tumors resulting in clinically serious gynecological problems in women of reproductive age. Approximately, 1% of leiomyosarcoma was reported to arise in a preexisting leiomyoma. However, the molecular basis o
Autor:
S. Tangjitgamol, H. T. See, S. Manusirivithaya, C. F. Levenback, D. M. Gershenson, J. J. Kavanagh
Publikováno v:
International Journal of Gynecologic Cancer. 14:804-814
Ovarian carcinoma is a malignant disease with a high rate of recurrence, necessitating repeated chemotherapy treatments. We conducted a retrospective study in patients with platinum- and paclitaxel-resistant ovarian, fallopian tubes and primary perit
Publikováno v:
International Journal of Gynecologic Cancer. 13:701-734
Despite advances in surgery and chemotherapy, less than 20% of patients with stage III or IV ovarian cancer survive long-term. In the past, cytotoxic regimens have been developed empirically, combining active agents at maximally tolerated doses, ofte
Publikováno v:
International Journal of Gynecologic Cancer. 12:710-714
The objectives of this phase II protocol were: 1) to determine the clinical activity of thiotepa combined with cisplatin in suboptimally debulked advanced epithelial ovarian carcinoma as first-line chemotherapy, 2) to determine by surgery the respons